Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Icodec and Semaglutide in Type 2 Diabetes
NCT05813912Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2023
- Primary completion
- Apr 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of insulin icodec and semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Change in Glycated Haemoglobin at Week 52. Started Sep 2023; status: completed.
02
Drugs
insulin icodecsemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05813912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813912.